These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10780196)

  • 1. [Bepridil: importance of serum level in treatment surveillance].
    Viallon A; Laporte-Simitsidis S; Pouzet V; Venet C; Tardy B; Zéni F; Bertrand JC
    Presse Med; 2000 Apr; 29(12):645-7. PubMed ID: 10780196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum bepridil concentration and corrected QT interval.
    Matsui K; Mukai Y; Sakakura K; Wada K; Nakamura T; Kawabata A; Terakawa N; Hayakawa N; Kusano K; Hosomi K; Yokoyama S; Takada M
    Int J Clin Pharmacol Ther; 2021 Jan; 59(1):63-70. PubMed ID: 33026317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
    Yasuda M; Nakazato Y; Sasaki A; Kawano Y; Nakazato K; Tokano T; Daida H
    Circ J; 2006 Jun; 70(6):662-6. PubMed ID: 16723784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics.
    Shiga T; Hashiguchi M; Naganuma M; Suzuki A; Hagiwara N
    Ther Drug Monit; 2013 Jun; 35(3):367-73. PubMed ID: 23666576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bepridil and torsades de pointes: are the precautions of use respected?].
    Viallon A; Page Y; Lafond P; Guy C; Cusey I; Tardy B; Zeni F; Lapierre B; Bertrand JC
    Therapie; 1994; 49(5):431-4. PubMed ID: 7855758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil.
    Yoshiga Y; Shimizu A; Yamagata T; Hayano T; Ueyama T; Ohmura M; Itagaki K; Kimura M; Matsuzaki M
    Circ J; 2002 Nov; 66(11):1024-8. PubMed ID: 12419934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol].
    Guy JM; André-Fouet X; Porte J; Bertrand M; Lamaud M; Verneyre H
    Ann Cardiol Angeiol (Paris); 1991 Nov; 40(9):541-5. PubMed ID: 1776799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of bepridil: from review of the European data.
    Coumel P
    Am J Cardiol; 1992 Apr; 69(11):75D-78D. PubMed ID: 1553894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bepridil produces prominent bradycardia-dependent QT prolongation in patients with structural heart disease.
    Sadanaga T; Ogawa S
    J Electrocardiol; 2007; 40(5):426-31. PubMed ID: 17531251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
    Isbister GK; Balit CR; Macleod D; Duffull SB
    J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
    Ly T; Ruiz ME
    Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced prolongation of the QT interval.
    Roden DM
    N Engl J Med; 2004 Mar; 350(10):1013-22. PubMed ID: 14999113
    [No Abstract]   [Full Text] [Related]  

  • 15. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsades de pointes associated with ziprasidone.
    Heinrich TW; Biblo LA; Schneider J
    Psychosomatics; 2006; 47(3):264-8. PubMed ID: 16684946
    [No Abstract]   [Full Text] [Related]  

  • 17. Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone.
    Takahara A; Nakamura Y; Sugiyama A
    Eur J Pharmacol; 2008 Oct; 596(1-3):127-31. PubMed ID: 18786527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
    Vieweg WV; Wood MA
    Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.